Entyvio maintenance – pro
Entyvio is a monoclonal antibody that binds to integrin α4β7 (LPAM-1, lymphocyte Peyer’s patch adhesion molecule 1), which provides gut-selective anti-inflammatory activity.
There is literature support for continuing this drug after an initial response. GEMINI III demonstrate that vedolizumab is an effective and well tolerated drug. The results of the GEMINI 1 and GEMINI 2 randomized, placebo-controlled multicenter trials of induction and maintenance therapy in Crohn’s disease and ulcerative colitissupport contnued treatemtn that was requested. In the trial of maintenance therapy by Feagan et al , patients in either cohort who had a response to vedolizumab at week 6 were randomly assigned to continue receiving vedolizumab every 8 or 4 weeks or to switch to placebo for up to 52 weeks. Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis.
McLean LP, Shea-Donohue T, Cross RK (September 2012). “Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease”. Immunotherapy. 4 (9): 883–98
Mosli MH, Feagan BG (March 2013). “Vedolizumab for Crohn’s disease”. Expert Opin Biol Ther. 13 (3): 455–63.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A (August 2013). “Vedolizumab as induction and maintenance therapy for ulcerative colitis”. N. Engl. J. Med. 369 (8): 699–710.